{"id":"NCT02008942","sponsor":"PLx Pharma","briefTitle":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients","officialTitle":"Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2013-12-11","resultsPosted":"2015-09-04","lastUpdate":"2016-03-10"},"enrollment":57,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"PL2200 Aspirin Capsules","otherNames":[]},{"type":"DRUG","name":"Enteric-coated aspirin caplets","otherNames":[]}],"arms":[{"label":"PL2200 Aspirin Capsules","type":"EXPERIMENTAL"},{"label":"Enteric-coated aspirin caplets","type":"ACTIVE_COMPARATOR"}],"summary":"This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric coated aspirin, when administered to patients with diabetes","primaryOutcome":{"measure":"Time to 99% Inhibition of Serum Thromboxane","timeFrame":"11 days","effectByArm":[{"arm":"PL2200 Aspirin Capsules","deltaMin":26.71,"sd":62.758},{"arm":"Enteric-coated Aspirin Caplets","deltaMin":64.57,"sd":72.842}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":57},"commonTop":["Upper Respiratory Infection"]}}